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Down syndrome (DS, trisomy 21) is associated with
developmental abnormalities and increased leu-
kemia risk. To reconcile chromatin alterations
with transcriptome changes, we performed paired
exogenous spike-in normalized RNA and chro-
matin immunoprecipitation sequencing in DS
models. Absolute normalization unmasks global
amplification of gene expression associated with
trisomy 21. Overexpression of the nucleosome
binding protein HMGN1 (encoded on chr21q22) re-
capitulates transcriptional changes seen with trip-
lication of a Down syndrome critical region on
distal chromosome 21, and HMGN1 is necessary
for B cell phenotypes in DS models. Absolute exog-
enous-normalized chromatin immunoprecipitation
sequencing (ChIP-Rx) also reveals a global in-
crease in histone H3K27 acetylation caused by
HMGN1. Transcriptional amplification downstream
of HMGN1 is enriched for stage-specific programs
of B cells and B cell acute lymphoblastic leukemia,
dependent on the developmental cellular context.
These data offer a mechanistic explanation for DS
transcriptional patterns and suggest that further
study of HMGN1 and RNA amplification in diverse
DS phenotypes is warranted.1898 Cell Reports 25, 1898–1911, November 13, 2018 ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://INTRODUCTION
Down syndrome, or constitutional trisomy of chromosome
21 (+21), causes numerous developmental and phenotypic
changes at the level of the whole organism. Cell biological
studies of Down syndrome compared to euploid cells have re-
ported diverse alterations associatedwith +21, but themolecular
basis for most of these is not clear. Two general theories, which
are not mutually exclusive, attempt to explain Down syndrome
phenotypes as either related to aneuploidy itself (i.e., simply
having an additional copy of genetic material) or due to dosage
increases of specific genes on chromosome 21 (Beach et al.,
2017; Bonney et al., 2015; Roper and Reeves, 2006).
Trisomy 21 is highly associated with acute leukemia. Individ-
uals with Down syndrome have at least a 20-fold increased
risk of developing B cell acute lymphoblastic leukemia (B-ALL)
compared to non-Down syndrome individuals (Berger, 1997).
Chromosome 21 is also the most common somatically gained
whole chromosome in the leukemia cells of individuals without
Down syndrome (Heerema et al., 2007). Additionally, interstitial
amplification of a portion of the long arm of chromosome 21
(iAMP21) is seen in a specific subtype of B-ALL and is associated
with a poor prognosis (Harrison et al., 2014; Li et al., 2014).
Furthermore, some individuals with Down syndrome develop-
mental phenotypes have triplication of only focal segments of
chromosome 21 (Korenberg et al., 1994). This can involve one
of the so-called Down syndrome critical regions (DSCRs) on
chr21q22, which overlaps with the iAMP21 region in B-ALL
and a similar region of recurrent somatic amplification in acuteuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Triplication of a Down SyndromeCritical Region or HMGN1Overexpression Alone Results in Increased RNA per Transcript per Cell
(A) Log2 fold change per transcript from RNA-sequencing of progenitor B cell colonies from Ts1Rhr compared to wild-type (top) and from HMGN1-OE transgenic
versus wild-type (bottom) bone marrow. n = 3 biological replicates per genotype. Plots on the left are median read count normalized between samples
(‘‘Relative’’), and plots on right are ERCC spike-in per cell-normalized (‘‘Absolute’’). Distribution compared to the null hypothesis of no difference between ge-
notypes using single sample t test.
(B) The data from (A) are plottedwith each dot representing a single gene’s expression quantitated in the indicated genotypes. The dotted line represents the unity
line of no difference between genotypes. The contour lines and legend represent high (green) to low (blue) relative bin density. Red and blue numbers represent
the number of genes that increase or decrease, respectively, in Ts1Rhr or HMGN1 versus wild-type (fold-change >1.5, p < 0.05). FPKM, fragments per kilobase of
transcript per million mapped reads; nFPKM, ERCC-normalized FPKM.
(C) Fold change in expressed transcripts (FPKMR0.5) quantitated by relative or absolute spike-in normalization in progenitor B cells of the indicated genotypes
were binned into 100 groups ranked by expression level in wild-type cells. Each point is the mean log2 fold change in the bin, error bars are 95% confidence
intervals. The red line represents non-linear curve fit of the binned data points.
(legend continued on next page)
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myeloid leukemia (AML) (Moorman et al., 2010; Mro´zek et al.,
2002; Rand et al., 2011). Together, these data suggest that
genes in the DSCR might be responsible for at least some
Down syndrome developmental and cancer phenotypes.
Many studies indicate that Down syndrome cells have
genome-wide epigenomic alterations, not confined to chromo-
some 21, when compared to euploid cells. These include
changes in gene expression (Costa et al., 2011; Letourneau
et al., 2014; Lockstone et al., 2007), RNA content (Hamurcu
et al., 2006), histone modifications (Lane et al., 2014; Letourneau
et al., 2014), nucleosome spacing (Kahmann and Rake, 1993),
and DNA methylation (Lu et al., 2016; Mendioroz et al., 2015).
Yet, linking transcriptional and epigenomic changes directly to
chromosome 21 or specific triplicated genes has been chal-
lenging because of other genetic and phenotypic heterogeneity
within cohorts of Down syndrome individuals. A recent study
analyzed otherwise isogenic cells from a pair of identical twins
who were discordant only for trisomy 21 (Letourneau et al.,
2014). Those experiments revealed alterations in gene expres-
sion and histone modifications across all chromosomes in
Down syndrome cells, in a pattern that suggested trisomy 21
modulates global gene regulation in discrete domains. The au-
thors coined the term ‘‘gene expression dysregulation domains’’
(GEDDs) as a possible unifying characteristic of +21 cells, and
they also detected similar expression patterns in an animal
model of Down syndrome that triplicates 65mouse chromosome
21 orthologs. The culprit gene(s) were not identified but they and
others postulated that future studies should attempt to identify
chromosome 21 gene products that could globally modify the
epigenome (Pope and Gilbert, 2014).
We previously showed that B cells from Down syndrome
mouse models and B-ALL leukemias from patients with Down
syndrome have epigenomic changes compared to euploid cells
(Lane et al., 2014). We found that among the 31 genes triplicated
in the Ts1Rhr Down syndrome mouse model, the most critical
gene for maintaining aberrant B cell phenotypes associated
with +21wasHmgn1, which encodes a nucleosome binding pro-
tein that modulates chromatin compaction and gene expression.
We therefore hypothesized that HMGN1 overexpression could
mediate trisomy 21-associated epigenomic and chromatin regu-
latory alterations.
RESULTS
Genome-wide Transcriptome Amplification in +21
Models Revealed by Absolute Normalization
Progenitor B cells from Ts1Rhr mice, which model Down syn-
drome by triplicating 31 genes on mouse chr16 orthologous to
a DSCR on human chr21q22, have genome-wide differences in
histone modifications compared to wild-type cells (Lane et al.,
2014). Despite these widespread epigenomic changes, tran-
scriptome analysis in the same B cells revealed only a small sub-
set of genes significantly increased or decreased in expression.
This is consistent with studies in Down syndrome cells and(D) Venn diagrams showing (top) the overlap of the top 200 most upregulated
significantly enriched gene sets (FDR <0.05) in gene set enrichment analysis (GS
using data from either relative or absolute normalized expression analysis.
1900 Cell Reports 25, 1898–1911, November 13, 2018other +21 models that show a modest number of genes with dif-
ferential expression compared to diploid cells, despite global
changes in epigenomic modifications. To reconcile this conun-
drum, we performed a series of experiments to evaluate the
transcriptome and epigenome of cells that model trisomy 21.
To improve whole transcriptome profiling, we performed RNA-
sequencing (RNA-seq) in the presence of ‘‘spiked-in’’ non-
mammalian synthetic ERCC (External RNAControls Consortium)
RNA controls for normalization of RNA content per cell (Lin et al.,
2012; Love´n et al., 2012). The advantage of normalizing to an
exogenous RNA control is that it allows comparison of samples
based on absolute RNA per cell, rather than normalizing to the
median measured RNA in each sample. To our surprise, we
found that pro-B cells from the Ts1Rhr mouse produced more
RNA transcripts per gene per cell than wild-type pro-B cells
(p < 0.0001 by t test for difference from no change) (Figures 1A
and 1B). The increase in RNA output was evident in genes
located on all chromosomes, but the magnitude of transcrip-
tional change was not the same across all mRNAs. Genes that
were not expressed in wild-type cells remained silenced, and
the highest expressed genes were less strongly affected in
Ts1Rhr pro-B cells. The per-cell increase in RNA expression in
cells from the Ts1Rhr model was most evident among the genes
expressed the low- to mid-range (Figure 1C).
Spike-in normalization did not interfere with detection of the
most differentially expressed genes or resulting gene expression
signatures in these B cell progenitors. The 200 most increased
genes in Ts1Rhr as compared to wild-type cells were highly
overlapping in the absolute- and relative-normalized datasets
(p < 0.0001 by Fisher’s exact test, Figure 1D). Gene set enrich-
ment analysis (GSEA) (Subramanian et al., 2005) applied to all
expressed genes in both datasets identified many of the same
signatures (Figure 1D; Data S1). Therefore, per-cell normalization
added additional insights to traditional gene expression profiling
by revealing a low-level global increase in RNA per-gene in
Ts1Rhr cells. At the same time, absolute normalization pre-
served identification of the highly differentially expressed genes
as seen with relative normalization techniques.
To validate the association between polysomy of human chro-
mosome 21 and increased RNA, we analyzed human retinal
pigment epithelium (RPE) cells that were engineered to carry ex-
tra copies of specific chromosomes using microcell-mediated
chromosome transfer (MMCT) (Lane et al., 2014). Consistent
with our findings from murine Ts1Rhr pro-B cells, RPE cells
with 1 or 2 extra copies of human chromosome 21 also con-
tained more RNA per cell than euploid RPE cells (Figure S1A).
HMGN1 Overexpression Recapitulates RNA
Amplification Seen in the Larger DSCR Triplication
We previously found that Hmgn1 was the chr21q22 orthologous
gene most essential to promote progenitor B cell self-renewal
when amplified in the Ts1Rhr mouse model (Lane et al., 2014).
Given that HMGN1 promotes chromatin accessibility, modifica-
tions in post-translational histone marks, and expressiongenes in Ts1Rhr B cell progenitors compared to wild-type, or (bottom) the
EA) in the 3,402 gene sets in ‘‘C2 CGP’’ collection in MSigDB (Broad Institute)
changes in genes regulated by nucleosome configuration (Catez
et al., 2002; Lim et al., 2005; Rochman et al., 2009), we hypoth-
esized that it might be responsible for the transcriptional ampli-
fication associated with Down syndrome and the Ts1Rhr model.
Therefore, we analyzed cells from a transgenic model that over-
expresses only HMGN1 (HMGN1-OE), at 2-fold protein levels
compared to wild-type cells (Bustin et al., 1995). When we per-
formedRNA-seqwith spike-in controls, we saw global amplifica-
tion of expressed genes in HMGN1-OE cells that was not evident
when using median normalization, similar to what we observed
in Ts1Rhr cells (Figures 1A and 1B). There were no significant
differences in cell-cycle status between HMGN1-OE and wild-
type cells that might contribute to changes in RNA content
(Figure S1B).
We next measured median-normalized RNA expression in
low, moderate, and high FPKM (fragments per kilobase of tran-
script per million mapped reads) bins. We observed a small rela-
tive increase in ‘‘low-expressed’’ genes and decrease in ‘‘high-
expressed’’ genes in Ts1Rhr when compared to wild-type
cells using median normalization (Figure 2A). This was similar
to what was reported in the description of GEDDs in human
+21 cells and mouse cells from the Ts65Dn Down syndrome
model (Letourneau et al., 2014). However, when we used
spike-in normalization, we found that all gene groups were
increased in expression in Ts1Rhr and HMGN1-overexpressing
cells (Figure 2A). Thus, the dominant expression change in
Ts1Rhr B cells may be global transcriptional amplification,
possibly via the activity of HMGN1.
We previously found that the genes whose expression was
most affected in Ts1Rhr pro-B cells and in patients with Down
syndrome-associated leukemias overlapped with polycomb
repressor complex 2 (PRC2) ‘‘targets’’ and genes associated
with H3K27 trimethylation (the histone mark catalyzed by
PRC2 activity) (Lane et al., 2014). These were particularly en-
riched in so-called ‘‘bivalent’’ genes in wild-type cells marked
simultaneously by both active (H3K4me3) and inactive
(H3K27me3) histone marks. Here, we found that although abso-
lute normalization revealed a larger number of genes whose
expression was amplified in the setting of HMGN1 overexpres-
sion compared to median normalization, the amplified genes in
the ‘‘low to mid’’ expression level at baseline in wild-type cells
were those genes marked with both active and repressive his-
tone marks (Figure 2B) and enriched for known targets of
EZH2 (the catalytic subunit of PRC2) in hematopoietic stem cells
(Figure 2C). These findings are consistent with the established
function of HMGN1 to relax chromatin compaction and modify,
but not on its own initiate, transcription. Genes that are active
but ‘‘poised’’ for higher expression, as indicated by bivalent
chromatin marks at baseline, may be most likely to increase in
expression when additional HMGN1 is present.
RNA Amplification by HMGN1 Is Rapid and Requires Its
Nucleosome Binding Residues
To determine if increased RNA output in the setting of HMGN1
overexpression is direct, we generated human B cell lines
(euploid for HMGN1 copy number at baseline) with a doxycy-
cline-inducible HMGN1 cassette (Figure 3A). As a control, we
used an HMGN1 cDNA encoding a protein with two serine resi-dues in the nucleosome binding domain mutated to glutamate
(HMGN1-SE), which abrogates its ability to bind to nucleosomes
(Prymakowska-Bosak et al., 2001). Overexpression of HMGN1
increased the total RNA content per cell within hours after the
addition of doxycycline (Figure 3B). The increase in RNA output
required the ability of HMGN1 to bind to the nucleosome
because induction of the HMGN1-SE mutant did not increase
RNA content compared to cells containing an empty expression
cassette. To rule out that the increased RNA per cell in HMGN1-
overexpressing cells was due to a change in the rate of RNA
turnover, we performed a pulse-chase experiment before and
after induction of HMGN1. The rate of labeled RNA decay in
HMGN1 overexpressing cells was similar to that in control
HMGN1-SE overexpressing cells (Figure S2A).
In some contexts, the amount of RNA per cell correlates with
cell-cycle status, cell size, and growth rate (Darzynkiewicz
et al., 1979; Padovan-Merhar et al., 2015). To test for this possi-
bility at the single-cell level, we analyzed collections of cells in a
time course after induction of HMGN1 using several methods,
including a suspended microchannel resonator (SMR) device
to measure the buoyant mass of a cell with femtogram precision
(Cermak et al., 2016), a Coulter counter to measure single-
cell volume, and a microfluidic hydrodynamic trap array to
directly observe single-cell proliferation kinetics (Kimmerling
et al., 2016). We saw no difference in buoyant mass, cell volume,
or single-cell interdivisionary time between HMGN1 overex-
pressing cells and controls within the first 6 hr after doxycycline
induction (Figures S2B–S2D). These data suggest that HMGN1-
overexpressing cells are not cycling or generating mass from
cell-extrinsic sources more rapidly than controls.
We next performed RNA-seqwith exogenous controls in B cell
lines 6 hr after induction of wild-type HMGN1 or the nucleosome
binding incompetent HMGN1-SE mutant. Similar to what we
observed in the primary progenitor B cells, absolute normaliza-
tion revealed a global increase in per transcript RNA content
measured per cell, averaging 1.3-fold per gene across the
genome (Figures 3C, S3A, and S3B). When we compared gene
expression in HMGN1-overexpressing cells to HMGN1-SE over-
expressing cells, ranked by expression level in the HMGN1-SE
control, we observed transcript amplification in most genes
with baseline expression of >0.5 FPKM (Figures 3C and 3D).
Standard relative read count normalization between samples
did not detect the same degree of global change in gene
expression.
To ask if the RNA increase in cells overexpressing HMGN1 is
directly related to greater nascent transcription per gene, we
performed thiol(SH)-linked alkylation for the metabolic labeling
of RNA (SLAM-seq) (Herzog et al., 2017). SLAM-seq utilizes
4-thiouridine incorporation to quantitate newly synthesized tran-
scripts as a fraction of the total transcripts of a given gene. The
data can be expressed as the ‘‘conversion fraction,’’ referring
to the iodoacetamide-induced alkylation that converts labeled
residues during the reverse transcription step prior to next gen-
eration sequencing. Cells induced to overexpress HMGN1
generated more nascent transcripts per gene during the 5-hr
labeling period compared to cells overexpressing the HMGN1-
SE mutant or uninduced controls (p < 1e9, Figure 3E). An in-
crease in conversion fraction was evident globally (Figures 3FCell Reports 25, 1898–1911, November 13, 2018 1901
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able genes. Consistent with the increased RNA per cell being
secondary to increased transcription, we also found that pre-1902 Cell Reports 25, 1898–1911, November 13, 2018mRNA levels, measured using nascent intron expression
from SLAM-seq and validated by exon and intron real-time
qPCR, increased after HMGN1 induction (Figures S3D and
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(A) Western blotting of lysates from Nalm6 B-ALL cells stably infected with a lentivirus that contains a doxycycline-inducible human HMGN1 cDNA (N1), an
HMGN1 mutant that lacks the ability to bind to the nucleosome, HMGN1-S20,24E (SE), or empty vector (V) at baseline (0 hr), 3 hr, and 6 hr after the addition of
doxycycline to the culture medium.
(B) Total RNA content measured by fluorometric assay in biological triplicates of the indicated cells relative to empty vector over a time course after addition of
doxycycline to the culture medium. n = 3 biological replicates. Samples compared by t test.
(legend continued on next page)
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S3E). While several mechanistic functions, some indirect, attrib-
uted to HMGN1 at the chromatin could be contributing to
expression changes (Catez et al., 2002; Deng et al., 2015; Ratt-
ner et al., 2009), these data support the assertion that HMGN1
overexpression results in an increase in nascent transcription,
and this phenotype is dependent on HMGN1 binding to the
nucleosome.
Spike-In Chromatin Immunoprecipitation and
Sequencing Unmasks Global H3K27 Hyperacetylation
by HMGN1 Overexpression
Next, we wanted to quantitate the immediate consequences of
HMGN1 induction on histone marks. Quantitation of locus-
specific histone mark changes in the setting of perturbations
that cause global alterations in the epigenome is challenging.
Local changes associated with HMGN1 overexpression could
be obscured using traditional chromatin immunoprecipitation
and sequencing (ChIP-seq) bioinformatics, which also relies on
normalization to median read counts between samples and
might hide a widespread effect (Chen et al., 2015).
Therefore, we performed ChIP-seq for histone marks in cells
with inducible HMGN1 expression normalized to spiked-in exog-
enous nuclei from Drosophila S2 cells (‘‘ChIP-Rx,’’ or chromatin
immunoprecipitation with reference exogenous genome) (Or-
lando et al., 2014). Six hours after induction of HMGN1, we
observed a global increase in H3K27 acetylation compared to
baseline (p < 0.0001, Figures 4A and 4B). This finding is consis-
tent with more globally active chromatin at promoters and/or
enhancers, and with the increase in transcriptional output per
cell we detected using per cell-normalized RNA-seq. We
observed a similar genome-wide increase in promoter-associ-
ated H3K4me3 after induction of HMGN1, also consistent with
the observed increased transcription. Notably, ChIP-seq anal-
ysis using traditional median read count normalization did not
detect the global increase in H3K27ac or H3K4me3 (Figures
4A and 4B).
Next, we performed an integrated analysis of ChIP-seq and
RNA-seq in B cells after induction of HMGN1 or the HMGN1-SE
mutant. The normalized ChIP-seq peak heights for H3K27ac
were significantly higher within 1 kb of the promoters of genes
that were most increased in expression in the setting of HMGN1(C) Left: expression ratios across all expressed genes from RNA-sequencing of Na
SE, calculated using relative or absolute spike-in normalization (n = 4 biological re
HMGN1 to HMGN1-SE expressing Nalm6 cells after doxycycline induction using r
difference between conditions. The contour lines and legend represent high (green
of genes that increase or decrease, respectively, in HMGN1-WT versus HMGN1-S
million mapped reads; nFPKM, ERCC-normalized FPKM.
(D) Distribution of fold change in individual gene expression between HMGN1 and
(red) RNA-seq analysis. Positive fold change = higher in HMGN1 compared to HM
HMGN1-SE cells, similarly to Figure 2A. Distributions compared by t test.
(E) Cumulative distribution function plot of SLAM-seq data for active genes show
compared to uninduced cells. The red line represents cells after induction of HMG
(n = 3 biological replicates). The rightward shift of the curves suggests that per ge
uninduced cells or to cells expressing the HMGN1-SE mutant. Changes in distrib
(F) Binned plot of active genes ranked by nascent transcript fraction in uninduced c
nascent transcripts generated in the labeling period relative to pre-existing tran
represent 95% confidence intervals of the mean.
(G) Conversion fraction (nascent transcripts per total transcripts) of an illustrative
induction of the HMGN1-SE mutant. Error bars represent SEM.
1904 Cell Reports 25, 1898–1911, November 13, 2018induction (Figure 4C). These data show that gene expression
changes within 6 hr following induction of HMGN1 are associated
with specific histone marks and suggest that measurement of
histone marks ‘‘classically’’ associated with active expression
(e.g., H3K27ac) are preserved when measured by per cell-
normalized ChIP-seq.
In addition to its association with promoters and near tran-
scriptional start sites, H3K27ac is also associated with active
enhancers. Therefore, we tested the hypothesis that even in
the setting of global expression changes, the genes with the
greatest increase in expression after HMGN1 induction might
be enriched for those associated with broad H3K27ac deposi-
tion in regulatory regions of developmental stage and lineage-
defining genes, the so-called ‘‘super enhancers’’ (Whyte et al.,
2013). Indeed, among genes expressed at baseline (FPKM >1)
in Nalm6 cells, those near super enhancers were more likely to
have a significant increase in gene expression (fold-change
>1.5, adjusted p value [adjP] <0.05) than those without an asso-
ciated super enhancer (16.7% versus 10.2%, p = 0.003 by Chi
square test with Yates correction). These data suggested that
HMGN1 overexpression might augment a cell’s pre-existing
transcriptional programs, rather than induce a wholesale change
in cell state. In support of this hypothesis, we observed no signif-
icant differences in the pattern of chromatin accessibility after
short-term HMGN1 induction, as measured by an Assay for
Transposase-Accessible Chromatin sequencing (ATAC-seq),
including at loci with increased expression and H3K27 acetyla-
tion (Figure S4A). Together, these findings suggest that
HMGN1 supports increased expression of pre-existing tran-
scriptional programs.
HMGN1 Promotes Upregulation of Developmental
Stage-Specific Pathways in B Cells
‘‘Transcriptional addiction’’ may be a hallmark of cancer (Franco
and Kraus, 2015). Based on our data, HMGN1 overexpression
and trisomy 21 could contribute to leukemia by enhancing
transcription. However, it remains unclear specifically how tran-
scriptional amplification promotes tumor growth and whether
this process differs by cellular context. One possibility is that
increased transcription allows a cell to overcome growth-limiting
conditions by increasing the activity of survival pathways.lm6 cells 6 hr after addition of doxycycline to overexpress HMGN1 or HMGN1-
plicates per condition). Right: dot plot of individual gene expression comparing
elative or absolute normalization. The dotted line represents the unity line of no
) to low (blue) relative bin density. Red and blue numbers represent the number
E (fold-change >1.5, p < 0.05). FPKM, fragments per kilobase of transcript per
HMGN1-SE overexpressing cells from relative (orange) or absolute normalized
GN1-SE. Plots are divided into low, mid, and high terciles by gene expression in
ing the log2 fold change in nascent reads during the labeling period in induced
N1 and the gray line represents cells after induction of the HMGN1-SE mutant
ne there are more transcripts generated after HMGN1 induction compared to
utions are significant at p < 1e9 by two-tailed t test.
ells (x axis) versus themean log2 fold change in the conversion ratio (number of
scripts) for genes in a bin, in induced or uninduced cells (y axis). Error bars
gene, PRDM1, in uninduced cells, cells after induction of HMGN1, or cells after
AB
C
0
1
2
3
4
R
el
at
iv
e 
pe
ak
 re
ad
 c
ou
nt
s
P<0.0001
P=0.19
P<0.0001
H3K27ac H3K27me3H3K4me3
0.
6
0.
8
1.
0
1.
2
1.
4
1.
6
H3K27ac Relative Normalization
R
P
M
+DOX
−DOX
0.
5
1.
0
1.
5
2.
0
2.
5
R
P
M
10
15
20
25
nR
P
M
+DOX
−DOX
5
10
15
20
25
30
35
40
nR
P
M
−DOX +DOX
0.
5
1.
0
1.
5
2.
0
R
P
M
P=0.22
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
R
P
M
P=0.052
5
10
15
20
25
30
35
nR
P
M
P<0.0001
0
10
20
30
40
nR
P
M
-5kb -2.5 TSS +2.5 +5kb
H3K4me3 -DOX
H3K4me3 +DOX
H3K27ac -DOX
H3K27ac +DOX
chr17: 25,620,000 25,625,000
WSB1
60 
0 
60 
0 
50 
0 
50 
0 
Absolute NormalizationRelative Normalization
chr17: 25,620,000 25,625,000
WSB1
60 -
1 
60 
1 
50 
1 
50 
1 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
R
P
M
nR
P
M
H3K27ac Absolute Normalization
H3K4me3 Relative Normalization H3K4me3 Absolute Normalization
−DOX +DOX
−DOX +DOX −DOX +DOX
P<0.0001+DOX
−DOX
+DOX
−DOX
-5kb -2.5 TSS +2.5 +5kb
-5kb -2.5 TSS +2.5 +5kb -5kb -2.5 TSS +2.5 +5kb
UP
DOWN
Figure 4. Absolute per Cell-Normalized Chromatin Immunoprecipitation Reveals Global Effects of HMGN1 Overexpression on Histone
Marks
(A) Metagene plots and read quantitation of H3K27ac and H3K4me3 ChIP-seq in Nalm6 cells stably expressing a doxycycline-inducible HMGN1 cDNA 6 hours
after addition of doxycycline or vehicle to the culture medium. Plots on the left are relative median read count-normalized ‘‘traditional’’ ChIP-seq, and on the right,
absolute per cell-normalized to sequencing reads from ChIP-seq of exogenous spiked-in Drosophila S2 cell nuclei. RPM, reads per million; nRPM, normalized
reads per million; x axis of metagene plots shows the transcriptional start site (TSS) and 5 kb upstream and downstream. Boxplots represent the distribution of
ChIP-seq peak height at each detected gene (compared by t test).
(B) Gene tracks showing a representative locus on chr17 where an increase in H3K27 acetylation after addition of doxycycline is only evident after applying per
cell absolute spike-in normalization.
(C) Relative read counts of histone marks at peaks within 1 kb of the TSS of genes that significantly (fold-change >1.5, p < 0.05) increased (UP, red) or decreased
(DOWN, blue) in expression after induction of HMGN1 overexpression. Distributions compared by t test.
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Figure 5. Lineage- and Leukemia-Specific Pathway Expression Is Enriched in Cells with Overexpression of HMGN1, and Hmgn1 Triplication
Is Necessary for Pro-B Cell Phenotypes Associated with the Ts1Rhr Model
(A) GSEA of RNA-sequencing data from Nalm6 preB-ALL cells after induction of HMGN1 or HMGN1-SE showing enrichment in B cell receptor signaling pathway
genes (BIOCARTA_BCR_SIGNALING) and in genes that distinguish preB-ALL from other types of ALL (PreB-ALL). Distribution plots shown on left (ES,
enrichment score; FDR, false discovery rate [adjusted p value]), and heatmaps of gene expression (blue, low; red, high) genes in the ‘‘core enrichment’’ from those
GSEA analyses are shown on the right.
(B) GSEA of RNA-sequencing data from primary B cell progenitors cultured from Ts1Rhr or HMGN1-OE transgenic bone marrow showing enrichment of STAT5
target genes and genes bound by STAT5 and B cell transcription factors in Ts1Rhr and HMGN1-OE B cells compared to wild-type (ES, enrichment score; FDR,
false discovery rate [adjusted p value]).
(legend continued on next page)
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Therefore, we tested for effects of HMGN1 overexpression or
chr21q22 triplication on developmental stage-specific and leu-
kemia-associated signaling pathways. Developing B cells and
B-ALLs can be classified as pre-B, with predominant growth
signaling via B cell receptor (BCR) pathways to SRC family
kinase activation and targets such as BCL6; or pro-B, with
signaling via cytokine receptor pathways to JAK/STAT activation
and targets such as the D type cyclins (Geng et al., 2015).
The model systems we tested represent these two B cell
subtypes based on developmental stage, cell surface markers,
and gene expression profile (humanNalm6 is a pre-B cell; mouse
B cells colonies grown in the presence of interleukin-7 are pro-B
cells). Therefore, we hypothesized that upon HMGN1 overex-
pression, Nalm6 cells might preferentially increase expression
of BCR signaling and pre-B ALL pathways, and pro-B cells
from Ts1Rhr or HMGN1-OE bone marrow may increase JAK/
STAT pathways.
We observed transcriptome changes supporting each of
these hypotheses. RNA-seq of Nalm6 cells after induction of
wild-type HMGN1 compared to the nucleosome binding-incom-
petent HMGN1-SE demonstrated specific enrichment of B cell
receptor (BCR) signaling pathway-associated genes and genes
that distinguish pre-B ALL from other subtypes of B-ALL (Fig-
ure 5A; Data S2) (Geng et al., 2015). At the chromatin, HMGN1
induction resulted in increased expression, H3K27 acetylation,
and HMGN1 binding to promoters of genes important in B cells,
such as PRDM1 and IRF4 (Figures S4A and S4B). Conversely,
BCL6, a zinc-finger transcription factor with repressive activity
at many BCR pathway genes in pre-B cells (Geng et al., 2015)
had decreased binding at the same promoters (Figure S4B),
consistent with the observed increased transcription. These
changes were associated with modest increases in protein level
of some BCR pathway members and enhanced phosphorylation
of AKT, a downstream target of tonic BCR signaling in Nalm6
cells (Figures S4C–S4E). Histone acetylation driven by transcrip-
tional co-activators such as the histone acetyltransferases
(HATs) CBP and p300 are known to act in opposition to BCL6
and its associated co-repressor complexes in B cells (Hatzi
et al., 2013). Furthermore, HMGN1 promotes HAT activity,
possibly via local steric changes that allow histonemodifying en-
zymes greater access to individual nucleosomes (Lim et al.,
2005). These data support the hypothesis that HMGN1 modu-
lates gene expression and histone mark alterations at ‘‘tunable’’
loci, such as at poised promoters and enhancers, possibly in
association with relative changes in activity of transcriptional
proteins.
Consistent with lineage-specific activity, in pro-B cells, tripli-
cation of 21q22 orthologs or overexpression of HMGN1 alone
was associated with enrichment of B-ALL-associated STAT5(C) Heatmaps showing expression of the top 50 genes in the ‘‘leading edge’’ o
HMGN1-OE B cell progenitors.
(D) Mouse genotypes tested in panels E-G and their associated copy number profi
intercross has three copies of the chromosome 21q22 orthologs, except for only
(E) Progenitor B cell colony numbers in 1st and 2nd passage derived from bone m
genotypes compared by t test, *p < 0.05).
(F) Relative H3K27 acetylation measured by intracellular flow cytometry in proge
(G) Relative RNA expression by real-time qPCR for Fgf13, Kit, and Hmgn1 in protarget genes and genes in chromatin regions marked by binding
of STAT5 and B cell lineage transcription factors (Figure 5B; Data
S2) (Katerndahl et al., 2017). Ts1Rhr and HMGN1-OE pro-B cells
were remarkably similar in their gene expression changes
compared to wild-type cells, especially in the subset of known
leukemia-associated STAT5 and B cell transcription factor-
bound genes (Figure 5C). The observed associations with
HMGN1 overexpression were cell-type-specific and not only
due to global increased transcription, because STAT5/pro-B
cell genes were not specifically enriched in Nalm6 pre-B cells
after HMGN1 induction, and BCR/preB-ALL signatures were
not enriched in pro-B cell colonies from Ts1Rhr or HMGN1-OE
mice. Together, these data suggest that in addition to modest
global transcriptional amplification, within a given cell type,
HMGN1 overexpression most significantly affects genes associ-
ated with lineage and maturation stage-specific transcriptional
programs.
Hmgn1 Triplication Is Necessary for Progenitor B Cell
Phenotypes Associated with the Ts1Rhr Down
Syndrome Model
To test if three copies of Hmgn1 were necessary for the
increased colony-forming activity (Lane et al., 2014) and tran-
scriptional phenotypes associated with triplication of 31 chro-
mosome 21q22 orthologs, we crossed Ts1Rhr mice with mice
engineered to lack one copy of Hmgn1 (Birger et al., 2003).
The resulting progeny included wild-type (two copies of
Hmgn1 and all other genes), Ts1Rhr (three copies of the 31
genes, including Hmgn1), and Ts1Rhr/Hmgn1+/ (two copies
of Hmgn1, but three copies of 30 other genes; black, red, and
gray, respectively, in Figures 5D–5G). Reversion of Hmgn1 to
two copies abrogated the increase in progenitor B cell colony-
forming activity (Figure 5E), increase in global H3K27 acetylation
(Figure 5F), and gene-specific increases in RNA expression (Fig-
ure 5G) associated with Ts1Rhr B cells. These data suggest that
triplication of Hmgn1 is required for at least several progenitor
B cell phenotypes associated with 21q22 DSCR triplication.
DISCUSSION
We have attempted to reconcile seemingly conflicting observa-
tions comparing epigenomic modifications and transcriptional
profiles in Down syndrome and euploid cells. Several studies
have noted global, genome-wide alterations in the epigenome
of +21 cells, including in CpG methylation (Lu et al., 2016; Men-
dioroz et al., 2015), global and locus-specific changes in the his-
tone marks H3K4me3, H3K27me3, and H3K27ac (Lane et al.,
2014; Letourneau et al., 2014), and even changes in the length
of spacing between sequential nucleosomes (Kahmann andf the STAT5 target gene signature from GSEA in wild-type (WT), Ts1Rhr, and
les for Hmgn1 and 30 other genes in the Ts1Rhr model. The Ts1Rhr/Hmgn1+/
two copies of Hmgn1.
arrow of mice of the indicated genotypes (for E–G, n = 3 biological replicates,
nitor B cells of the indicated genotypes harvested after passage 1.
genitor B cells of the indicated genotypes harvested after passage 1.
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Absolute per cell normalization of transcriptome
data may provide a mechanistic explanation for
some previous, incompletely explained observa-
tions in trisomy 21 cells, including and global RNA
and epigenomic changes. If the actual expression
pattern in trisomy 21 (or with HMGN1 over-
expression) is amplification that differentially af-
fects areas of baseline ‘‘high’’ or ‘‘low’’ expression
(left), then forced normalization to an equivalent
median signal between samples (blue arrow and
dotted line) would instead be interpreted as
decreased expression in baseline ‘‘high’’ ex-
pressed genes and increased expression in ‘‘low’’
expressed genes (right).Rake, 1993). However, gene expression profiling has detected
only modest changes in small numbers of genes that are often
not consistent across cell types or between studies. There is
even controversy as to whether the genes on chromosome 21
itself have a higher expression level in Down syndrome cells
by virtue of trisomy (Antonarakis, 2017).
Using cell count-normalized RNA-seq and ChIP-seq, we
found that otherwise isogenic models of Down syndrome have
increased RNA per cell compared to euploid cells. This tran-
scriptional amplification was evident across thousands of genes
and was further enriched at genes associated with certain chro-
matin marks. Overexpression of HMGN1, a nucleosome binding
protein encoded on chr21q22 that is known to relax chromatin
compaction and globally modulate epigenomic control, was
sufficient to recapitulate these transcriptional phenomena and
directly caused an increase in nascent transcription. These
data may provide a mechanistic explanation for a prior observa-
tion of increased RNA in peripheral blood mononuclear cells of
Down syndrome compared to non-Down syndrome individuals
(Hamurcu et al., 2006).
We propose that trisomy 21/HMGN1-mediated transcriptional
amplification could also offer a mechanism contributing to other
genome-wide changes observed in Down syndrome cells. While
the previously described specific domains of gene expression
dysregulation, ‘‘GEDDs’’ (Letourneau et al., 2014), are controver-
sial (Do et al., 2015), many studies have nonetheless observed
genome-wide epigenomic alterations in Down syndrome, not
confined to chromosome 21. HMGN1 is one possible culprit
chromosome 21 gene to cause global transcriptional changes,
given its ability to modulate chromatin (Pope and Gilbert,
2014), but it was unclear how HMGN1 might cause specific
expression patterns. Trisomy 21/HMGN1 transcriptional amplifi-
cation may offer one model, which could be relevant to many
transcriptional measurements in Down syndrome, not only for
interpreting GEDDs. By fitting to an equivalent median signal
between Down syndrome and euploid cells, genes with low
expression in euploid cells might appear relatively higher in
Down syndrome, and those with high expression might appear
relatively lower. Thus, the observed ‘‘flattening’’ of transcription
attributed to trisomy 21 (Pope and Gilbert, 2014) could be a
product of median normalization on an amplified transcriptome
(Figure 6).1908 Cell Reports 25, 1898–1911, November 13, 2018While the transcriptional changes we observed were ‘‘global,’’
in that they affected many genes throughout the genome and
in aggregate were associated with increased expression, the ef-
fect size was not identical at all loci, and not every gene was
affected. Transcriptome reshaping by HMGN1 was associated
with chromatin signatures at promoters, and in B cells, line-
age-defining genes were enriched for having susceptible base-
line chromatin and expression states. This led to an overall effect
where, although many genes were upregulated, there was
more pronounced activation of specific sets of B-lineage genes.
This may have contributed to the functional consequences in
B cell growth and signaling we observed. Knockout of HMGNs
changes the DNase hypersensitivity landscape and gene
expression in a tissue-specific manner (Deng et al., 2015), which
fits logically with what we found in the setting of HMGN1 overex-
pression. Furthermore, the concept that pre-existing chromatin
states shape the most affected genes in the setting of ‘‘global’’
transcriptional amplification is similar to what has been reported
for MYC-dependent changes (Nie et al., 2012; Walz et al., 2014;
Zeid et al., 2018), suggesting that this may be a recurrent mech-
anism of oncogenic gene expression alteration.
In patients with B-ALL, somatic gain of chromosome 21
frequently co-occurs with the t(9;22) BCR-ABL1 tyrosine kinase
rearrangement (Wetzler et al., 2004). Similarly, Down syndrome-
associated ALL is enriched for acquired mutations in cytokine
receptor and/or kinase signaling genes, such as CRLF2 and
JAK2 (Lee et al., 2016). One mechanistic hypothesis for this
epidemiologic association is that transcriptional amplification
via HMGN1 cooperates by facilitating increased output of acti-
vated signaling pathways in transformed B cells at the chro-
matin. Alternatively, transcriptional amplification could be more
generally oncogenic by enhancing multiple growth and survival
phenotypes, as some studies have shown that increased RNA
output is a common feature of transformed cells (Lin et al.,
2012; White, 2005). In either case, RNA increases mediated by
HMGN1 might offer improved relative fitness to a leukemia
cell. However, additional chromosome 21 genes are almost
certainly involved in Down syndrome phenotypes. For example,
enhanced interferon signaling was observed in several +21 cell
types, including B lymphoblastoid lines, attributed to increased
expression of interferon receptors located on chromosome
21 (Sullivan et al., 2016). We did not observe enrichment of
interferon pathways in our models, but neither the Ts1Rhr tripli-
cated region nor the minimally amplified chromosome 21
segment in iAMP21 B-ALL (Rand et al., 2011) includes interferon
receptor gene loci. This underscores the complexity of directly
relating specific chromosome 21 gene dosage to widespread
Down syndrome phenotypes across cell types.
The HMGN family of proteins may have a more general role in
cancer. The closely related HMGN2 enhances STAT5 function
and chromatin accessibility downstream of the prolactin recep-
tor in breast cancer cells (Schauwecker et al., 2017), similar to
what we hypothesized for HMGN1 in proB-ALL cells. Also, of po-
tential therapeutic relevance, overexpression of HMGN family
members is associated with relative chemoresistance whereas
knockdown enhances chemosensitivity (He et al., 2015; Yang
et al., 2014). However, neither Ts1Rhr nor HMGN1-OE mice
develop spontaneous leukemia (Lane et al., 2014; Malinge
et al., 2012), which suggests, like in children with Down syn-
drome, cooperating events may be required to achieve fully
malignant transformation. Additional studies will be required to
understand the specific mechanisms by which RNA amplifica-
tion contributes to transformation and cancer cell survival, and
whether HMGN1 overexpression creates unique dependencies
that could be exploited for treatment.
It remains unclear how transcriptional amplification might
contribute to the developmental characteristics of Down syn-
drome. While Down syndrome phenotypes are complex and
likely polygenic (i.e., not simply caused by three copies of a
single gene), HMGN1 could shape the Down syndrome tran-
scriptome across lineages via its ability to decompact chromatin
and enhance transcription in tissue-specific contexts. In fact,
some Down syndrome-associated epigenomic changes might
even be secondary to transcription induced by HMGN1,
because chromatin density and transcription can modulate
epigenomic enzyme activity in some scenarios, rather than the
reverse (Yuan et al., 2012). These hypotheses should be tested
using existing models, keeping in mind that Down syndrome
abnormalities manifest in a variety of tissues, often with distinct
clinical and cellular features. We know that HMGNs can affect
transcription differently based on cell or tissue type (Kugler
et al., 2013). Therefore, the contribution of HMGN1 and tran-
scriptional amplification to diverse Down syndrome phenotypes
may need to be studied separately in each developmental
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-human HMGN1 dilution 1:1000 Bethyl A302-363A
Rabbit anti-human BCL6 dilution 1:1000 Cell Signaling Technology 14895S
Rabbit anti-human beta-Actin dilution 1:1000 Sigma SAB5500001
Rabbit anti-human CD79A dilution 1:1000 Santa Cruz sc-25604
Rabbit anti-human Lyn dilution 1:1000 Santa Cruz sc-15
Mouse anti-human Syk dilution 1:1000 Santa Cruz sc12-40
Rabbit anti-human H3K27me3 (ChIP) Cell Signaling Technology 9733
Rabbit anti-human H3K4me3 (ChIP) Abcam ab8580
Rabbit anti-human H3K27acetyl (ChIP) Abcam ab4729
Rabbit IgG Cell Signaling Technology 2729
Rabbit anti-human H3K27acetyl dilution 1:500 (Flow) Abcam ab4729
Rabbit anti-human phospho-Akt (Ser473) dilution
1:500 (Flow)
Cell Signaling Technology 4060
Goat anti-Rabbit IgG Alexa Fluor 555 dilution 1:1000 Invitrogen A21428
Chemicals, Peptides, and Recombinant Proteins
Recombinant mouse IL3 Gold Biotechnology 1310-03-2
B cell methylcellulose with IL7 Stem Cell Technologies M3630
Doxycycline hydrochloride Fisher Scientific BP26531
5-Bromouridine Sigma B7166
Trizol Life Technologies 15596018
ERCC Spike-in Thermo Fisher/Ambion 4456740
4-Thiouridine Sigma T4509
Puromycin dihydrochloride Gold Biotechnology P-600
Polybrene Santa Cruz sc-134220
Lipofectamine 2000 Life Technologies 11668500
RNase Sigma R6513
Critical Commercial Assays
Qubit RNA BR assay kit Life Technologies Q10210
Quantifluor RNA System VWR PAE3310
Agilent RNA 6000 Nano Kit Agilent 5067-1511
SimpleChIP enzymatic chromatin IP kit Cell Signaling Technology 9005
DNA-free DNA removal kit Invitrogen AM1906
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814
Power SYBR Green PCR master mix Applied Biosystems 4367659
Deposited Data
Raw and analyzed RNA-seq and ChIP-seq data This paper GEO: GSE121071 https://www.ncbi.nlm.nih.gov/geo/
Experimental Models: Cell Lines
Human: Nalm6 DSMZ ACC 128
Mouse: FL5.12 Laboratory of Anthony Letai N/A
RPE with MMCT of chr21 This paper and Lane et al.,
2014
N/A
Experimental Models: Organisms/Strains
Mouse: Ts1Rhr B6.129S6-Dp(16Cbr1-Fam3b)1Rhr/J,
backcrossed to C57BL/6J > 10 generations
Jackson Laboratory 005383
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse: HMGN1-OE, backcrossed to C57BL/6J > 10
generations
Laboratory of Michael Bustin N/A
Mouse: C57BL/6J wild-type Jackson Laboratory 0000664
Oligonucleotides
Primers for RT-PCR and ChIP-PCR, see Table S1 This paper N/A
Recombinant DNA
Plasmid: pCW57.1 (TRE-gateway; PGK-rtTA-2A-puro) This paper Addgene 41393
Software and Algorithms
GraphPad Prism 7 GraphPad Software https://www.graphpad.com/scientific-software/prism/
Morpheus N/A https://software.broadinstitute.org/morpheus/
Gene Set Enrichment Analysis Subramanian et al., 2005 https://www.broadinstitute.org/gsea/
SlamDunk v0.2.4 Herzog et al., 2017 https://github.com/t-neumann/slamdunk
ROSE Whyte et al., 2013 https://bitbucket.org/young_computation/roseCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andrew
Lane (andrew_lane@dfci.harvard.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal studies
All animal experiments were performed with approval of the DFCI Institutional Animal Care and Use Committee (IACUC) and accord-
ing to Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) standards. All mice usedwere as previously
described (Lane et al., 2014), except for Hmgn1 knockout mice were as described in Birger et al. (2003)). All transgenic strains were
crossed > 10 generations to a C57BL/6J background. Ts1Rhr/Hmgn1+/ mice were generated by crossing Hmgn1/ with Ts1Rhr
(Jackson Laboratory, 005383) animals. Bone marrow harvested for progenitor B cell analysis was from 6-8-week-old randomly
selected male and female littermates, co-housed separately by sex in specific pathogen-free environments.
Cell lines
The human pre-B leukemia cell line Nalm6was fromDSMZ, cell identity verified by STR profiling, and themouse pro-B cell line FL5.12
was obtained from the laboratory of Anthony Letai at DFCI. Retinal pigment epithelial (RPE) cells harboring extra copies of chromo-
somes generated by microcell-mediated chromosome transfer were as previously described (Lane et al., 2014). Unless otherwise
noted, all cells were cultured at 37C with 5% CO2 in RPMI 1640 supplemented with 10% fetal bovine serum (GIBCO, 10438026),
1% penicillin/streptomycin (GIBCO, 15140122), and 1% GlutaMAX (GIBCO, 35050061). FL5.12 cells were cultured in complete
RPMI media supplemented with 10 ng/ml mouse rIL-3 (Gold Biotechnology 1310-03-2).
METHOD DETAILS
Primary progenitor B cell colonies
Whole bone marrow was harvested from 6-8-week-old mice and red blood cells were lysed. Cells were plated in B cell methylcel-
lulose media containing interleukin-7 (Methocult M3630, Stem Cell Technologies) in 35 mm dishes at 2x105 cells/ml. Colonies
were collected by pooling the cultures after 7 days of growth.
Inducible expression of HMGN1
Human or mouse HMGN1 cDNA (wild-type or encoding the nucleosome binding-deficient HMGN1 S20,24E mutant (Prymakowska-
Bosak et al., 2001)) was cloned into the pCW57.1 (pLIX_401) lentiviral tet-ON vector (Addgene). Viruswas produced in 293T cells using
standard procedures with Lipofectamine 2000 (Invitrogen, 11668027). Virus was harvested at 48 and 72 hours post-transfection and
subsequently concentrated by ultracentrifugation at 23,000 g for 2 hours at 4C. Actively dividing Nalm6 and FL5.12 cells were then
spinfected in the presence of virus and polybrene at 2000 g for 2 hours at 32C, and thenwere selected in puromycin after 48 hours. To
induce overexpression of HMGN1 in stably infected cells, 100 ng/ml doxycycline was added to the cultures for the indicated times.
Cell concentrationwas standardized across conditions. RNAwas quantitated using either a Nanodrop spectrophotometer, Qubit fluo-
rometric quantitation (ThermoFisher), or QuantiFluor RNA System (Promega) following manufacturers’ protocols.Cell Reports 25, 1898–1911.e1–e5, November 13, 2018 e2
Antibodies
Antibodies for western blotting and ChIP were HMGN1 (Bethyl, 302-363A), BCL6 (Cell Signaling Technologies, 14895S), beta-actin
(Sigma, SAB5500001), CD79A (Santa Cruz, sc-25604), LYN (Santa Cruz, sc-15), SYK (Santa Cruz, sc12-40), H3K27me3 (Cell Signaling
Technologies, 9733), H3K4me3 (Abcam, ab8580), H3K27ac (Abcam, ab4729), or control IgG (Cell Signaling Technologies, 2729S).
Pulse-chase measurements of RNA decay
RNA labeling and detection using bromouridine (BrU) was performed as previously described (Larsen et al., 2001). Briefly, cells were
cultured in the presence of doxycycline for 5 hours to induce HMGN1 or HMGN1-SE expression. 1 mM BrU was added to the
media and incubated for one hour. Cells were washed and media with doxycycline was replaced, and samples were taken for anal-
ysis at the indicated time points. Harvested cells were fixed, permeabilized, stained with an anti-BrU antibody in PBS, and analyzed
by flow cytometry. Controls included unlabeled cells and BrU-labeled cells treated with RNase.
Single-cell buoyant mass and interdivisionary time
Suspendedmicrochannel resonator (SMR)measurements of cell mass andmicrofluidic trap-based time-lapsemeasurements of sin-
gle-cell inderdivisionary timewere performed as previously described (Kimmerling et al., 2016; Son et al., 2012). Briefly, as in previous
SMR analyses, the device was placed on a copper heat sink/source connected to a heated water bath, maintained at 37C for the
duration of the experiment. The sample was loaded into the device from vials pressurized under air with 5%CO2. Tomeasure a sam-
ple of cells, we first flushed one bypass channel of the device with the cell sample. We next equalized the pressures upstream and
downstream of this bypass and induced a pressure drop across the SMR to begin flowing cells across the sensor. Each cell transiting
the sensor led to a resonant frequency shift directly proportional to the buoyant mass of the cell. To calculate this proportionality
constant and determine the final buoyant mass values, the SMR was calibrated by measuring a population of polystyrene beads
with a known buoyant mass (ThermoFisher, 4207a).
Briefly, for single-cell interdivisionary timemeasurements, cells were loaded into amicrofluidic device fabricated from a silicon-on-
insulator wafer with 17-mm deep flow channels. Fluidic connections were established by securing the devices to a Teflon manifold
with PEEK tubingmaintained at 37Cwith a recirculating water bath. Pressure-driven flow in the devicewas controlled with electronic
pressure regulators; all fluids were pressurized with 5% CO2. Single cells were manually loaded into the device by introducing a cell
sample at a concentration of 23 105 cells perml and flowing it into the trap lanes. For long-term growth and kineticsmeasurements, a
single cell was loaded in each of the 20 lanes of the device. Once a single cell was loaded in each lane, the bypass channels were
flushed to remove any remaining untrapped cells. For continued nutrient repletion, cell growth media was perfused through the
bypass channels at a flow rate of 100 ml h1 with a pressure drop applied along the bypass channels. A slight pressure drop was
concurrently introduced across the traps to ensure that the cells remained trapped and their progeny flowed downstream to unoc-
cupied traps. Time-since-division measurements were determined by manually tracking division events and subsequent trap loca-
tions for single cells throughout time-lapse image stacks. Single-cell volume measurements from bulk cultures were collected on an
automated cell counter (Beckman Coulter).
RNA sequencing
For RNA sequencing experiments, cells were stimulated in complete media with or without doxycycline or in methylcellulose media
as indicated. Each condition was processed in biological triplicate or quadruplicate, as indicated in the text (n = 3 or 4 biological rep-
licates per viral transduction per time point). After the indicated time, one million cells were counted, and RNA was extracted using
Trizol reagent (Invitrogen, 15596018) with attention paid to ensuring equal and consistent volume transfers. For per cell normalization,
1 ml of Mix #1 ERCC exogenous spike-in RNA (Ambion, 4456740, diluted 1:1000) was added to each RNA sample. Quality control of
total RNA was performed using the RNA Qubit Assay (Invitrogen) and the Bioanalyzer RNA Nano 6000 Chip Kit (Agilent). At least
100 ng of total RNA and a Bioanalyzer RNA Integrity Number of > 7.0 were required. Libraries were prepared using TruSeq RNA
Library Preparation Kit v2, Set A (Illumina, RS-122-2001). Sequencing was performed at the DFCI Molecular Biology Core Facilities
(MBCF). Bioinformatic processing of RNA-seq data, including with spike-in controls was as previously described (Lin et al., 2012;
Love´n et al., 2012). Briefly, sequences were aligned using Bowtie (version 0.12.2) to a human genome build to which sequences
of the ERCC synthetic spike-in RNAs (https://tools.thermofisher.com/content/sfs/manuals/cms_095047.txt) had been added. The
RPKM (Reads Per Kilobase of exon per Million) was then computed for each gene and synthetic spike-in RNA. We used a loess
regression to re-normalize the RPKM values, using only the spike-in values to fit the loess. The affy package in R provides a function,
loess.normalize, which performs loess regression on a matrix of values (defined using the parameter mat) and allows for the user to
specify which subset of data to use when fitting the loess (defined using the parameter subset, see the affy package documentation
for further details). For this application, the parametersmat and subsetwere set as amatrix of all RPKM values and the row-indices of
the ERCC spike-ins, respectively. The default settings for all other parameters were used. The result of this was a matrix of RPKM
values normalized to the control ERCC spike-ins.e3 Cell Reports 25, 1898–1911.e1–e5, November 13, 2018
Gene set enrichment analysis (GSEA)
GSEA (https://www.broadinstitute.org/gsea/) was performed using the Molecular Signatures Database (MSigDB) version 6.0 (Sub-
ramanian et al., 2005). Genes in each gene set are available at MSigDB or are in publications referenced in the text. Leading edge
analysis was performed in GSEA and visualized as heatmaps using Morpheus (https://software.broadinstitute.org/morpheus/).
SLAM-seq
For cell processing and sequencing, thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq) was performed as
described (Herzog et al., 2017). Briefly, Nalm6 cells harboring tet-on HMGN1 or HMGN1-SE mutant constructs were induced with
vehicle or 100 ng/ml doxycycline for 6 hours. During the last 5 hours of induction, 4-thiouridine was added to the culture medium
at 100 mM final concentration. After the 6-hour induction period, cells were harvested in Trizol, and RNA processing and thiol modi-
fication using 4 mg input RNA were performed as previously described (Herzog et al., 2017). For sequencing, libraries were prepared
using Illumina’s TruSeq Stranded mRNA kit according to the manufacturer’s instructions and sequencing was performed on a Next-
Seq 500 using a NextSeq 500/550 Mid Output v2 kit (150 cycles).
For data processing and analysis, forward and reverse reads from fastq files were merged and SlamDunk v0.2.4 (https://github.
com/t-neumann/slamdunk) was run using ‘‘slamdunk all’’ with default parameters (trimming 12bp from the 50 end, reporting up to
100 alignments for multi-mappers and activating the multi-mapper retention strategy, filtering for variants with a variant fraction of
0.2, and filtering for base-quality cutoff of R 27). Whole gene and 30 UTR annotations were obtained in BED format from the
UCSC table browser (https://genome.ucsc.edu/cgi-bin/hgTables, GRCh37/hg19, RefSeq Curated). Reads were filtered for having
R 2 T > C conversions. For SLAM-seq analysis, we sought to examine the effects of HMGN1 or HMGN1-SE overexpression on
nascent transcription. First, we limited analysis to genes with a peak expression in the top 25%of overall mRNA expression in at least
one sample. We also filtered for genes for which read conversion was detectable across all samples (suggesting at least a baseline
level of nascent transcription). These filtered steps resulted in 5,275 active genes utilized in all analyses. Fold changes in nascent
transcription upon HMGN1 or HMGN1-SE induction were calculated relative to the uninduced cells. The statistical significance of
the difference between distributions was assessed using a two-tailed t test (Figure 3E). To examine the relationship between basal
nascent transcription and the effect of HMGN1 induction, active genes were ranked by initial nascent transcription fraction and
binned into 50 evenly distributed bins (105 genes per bin). For each bin, the mean log2 fold change in nascent transcription was
plotted. Error bars represent 95% confidence intervals of the mean (Figure 3F). To visualize changes in nascent transcription at
individual genes, the mean nascent transcription fraction and standard error of the mean were plotted (Figure 3G).
To quantify changes in nascent pre-mRNA levels, we utilized the aligned read file (.bam file) of nascent (a.k.a. ‘‘converted’’) reads
generated by the SlamDunk pipeline. We filtered for genes with at least 10 total concordant (i.e., positive strand read upstream of
minus strand read) read pairs. Read pairs were considered emanating for pre-mRNA if their sequences overlapped introns by at least
5 bases. Pre-mRNA levels were quantified in units of fragments (read pairs) per million mapped reads (fpm) in the original dataset
(which included both converted and unconverted reads). To quantify only genes with sufficient coverage, a cut-off of 1 fpm averaged
in at least one condition was applied. After this threshold was applied, 7,402 genes remained. The log2 fold change of HMGN1-WT
overexpression or HMGN1-SE overexpression was computed versus the no doxycycline control (Figure S3D). The statistical signif-
icance of the difference in distributions was assessed by a two-tailed Welch’s t test.
Spike-in normalized ChIP-seq (ChIP-Rx)
For each immunoprecipitation,8million cells were cross-linked with 1% formaldehyde in RPMImedium for 10min at 37C, washed
in cold phosphate-buffered saline (PBS), resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, and complete
protease inhibitors (Roche)). Cross-linked Drosophila S2 cells were spiked into experimental cells in lysis buffer at one S2 cell per five
experimental cells and then sonicated to obtain chromatin fragments between 200 bp and 1200 bp, as previously (Orlando et al.,
2014). Sonicated chromatin was resuspended in IP buffer (1% triton, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1) and incu-
bated overnight at 4C with protein A/G magnetic beads (Dynal) conjugated to 10 mg of one of the following antibodies: H3K27me3
(Cell Signaling Technologies, 9733), H3K4me3 (Abcam, ab8580), H3K27ac (Abcam, ab4729), or control IgG (Cell Signaling
Technologies, 2729S). The IP was washed 6 times with RIPA buffer (50 mM HEPES, pH 7.6, 1 mM EDTA, 0.7% Na deoxycholate,
1% NP-40, 0.5 M LiCl), the DNA recovered by reversing the cross-links in 1% SDS, 0.1 M NaHCO3 for 8 h at 65
C, and then purified
using a QIAquick PCR purification kit (QIAGEN, #28104). Bioinformatic processing of ChIP-seq data with and without S2 chromatin
normalization (ChIP-Rx) were as previously described (Orlando et al., 2014). Briefly, libraries were sequenced using Illumina
NextSeq500 with single-end reads. Sequences were demultiplexed and aligned using Bowtie against a ‘‘genome’’ that combines
the human hg19 genome and theDrosophila dm3 genome. A complete description of the basis and derivation of the ChIP-Rx normal-
ization factor is detailed in Orlando et al. (2014). Briefly, we derived a normalization constant such that after normalization the signal
per reference cell is the same across all samples. The total ChIP-seq signal derived from the reference cells is the count of reads
aligning to the Drosophila genome, which was used to normalize the read counts in the experimental cells. Super-enhancers were
identified using ROSE (Whyte et al., 2013). ChIP-PCR validation was performed using the SimpleChIP enzymatic chromatin IP kit
(Cell Signaling Technology, #9005) per the manufacturer’s instructions.Cell Reports 25, 1898–1911.e1–e5, November 13, 2018 e4
H3K27ac and phospho-Akt flow cytometry
Cells were harvested and washed twice with PBS. For H3K27acmeasurement, cells were then treated with 4% paraformaldehyde in
PBS for 15 minutes on ice, followed by centrifugation for 5 minutes at 300 g. Next, cells were resuspended in cold 70% EtOH added
drop by drop while vortexing gently and then incubated overnight at 20C. Then, cells were washed twice with PBS and once with
PBS/1% FBS. Cells were permeabilized for 20 minutes with 0.25% Triton X-100 in PBS/1% FBS followed by incubation with primary
H3K27ac (Cell Signaling Technology 8173S) or phospho-Akt (Cell Signaling Technologies, 4060S) antibodies at 1:500 dilution for
30 minutes, and then secondary antibody (1:1000) (Life Technologies Goat anti-rabbit IgG cross-adsorbed antibody Alexa Fluor
555, A21428) for 2 hours at 4C in the dark, prior to flow cytometry analysis.
ATAC-seq
An Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) was performed using the Omni-ATAC protocol as
previously described (Corces et al., 2017). Briefly, 105 cells were resuspended in 1 mL of cold ATAC-seq resuspension buffer
(RSB; 10 mM Tris-HCl pH 7.4, 10 mM NaCl, and 3 mM MgCl2 in water). Cells were centrifuged at 500 g for 5 min in a pre-chilled
(4C) fixed-angle centrifuge, and the supernatant was carefully aspirated. Cell pellets were then resuspended in 50 mLRSB containing
0.1%NP40, 0.1% Tween-20, and 0.01%digitonin by pipetting up and down three times. This cell lysis reaction was incubated on ice
for 3min. After lysis, 1mLRSB containing 0.1%Tween-20 (without NP40 or digitonin) was added, and the tubes were inverted tomix.
Nuclei were then centrifuged for 10 min at 500 g in a pre-chilled fixed-angle centrifuge. Supernatant was removed and nuclei were
resuspended in 50 mL of transpositionmix (Corces et al., 2017) (2.5 mL transposase26 (100 nMfinal), 16.5 mL PBS, 0.5 mL 1%digitonin,
0.5 mL 10%Tween-20, and 5 mLwater) by pipetting up and down six times. Transposition reactions were incubated at 37C for 30min
in a thermomixer with shaking at 1000 rpm. Reactions were cleaned up with QIAquick PCR spin columns. Library quantitation and
number of amplification cycles was determined as described (Buenrostro et al., 2015). After sequencing on a NextSeq 500 per the
manufacturer’s instructions, we used ChiLin pipeline 2.0.0 for QC and preprocessing (Qin et al., 2016), Burrows-Wheeler Aligner
(BWA) for read mapping (Li and Durbin, 2009), Model-based Analysis of ChIP-Seq (MACS) as a peak caller (Zhang et al., 2008),
and DESeq2 for differential peak analysis (Love et al., 2014).
Quantitative RT-PCR
RNAwas prepared using the Trizol reagent (Invitrogen, 15596018), DNAwas removed from the final RNA product using the DNA-free
DNA Removal Kit (Invitrogen, AM1906), cDNA was prepared using the High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, 4368814), and quantitative PCR was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems,
4367659), all per the manufacturers’ instructions.
Primers
Oligonucleotide primer sequences for qRT-PCR and ChIP-PCR are in Table S1.
QUANTIFICATION AND STATISTICAL ANALYSIS
Except aswhere otherwise stated (e.g., specificRpackagesnamed in theMethodDetails section), Prismsoftware (GraphPad)wasused
for calculating statistical significance.Statistical tests used, numberofbiological and technical replicates, dispersionandprecisionmea-
sures for each experiment are detailed in the figure legends. Unless otherwise stated, for boxplots comparing per-gene expression by
genotype, boxes represent the interquartile range and the whiskers extend to 1.5x of the range in either direction. The horizontal line
within the box represents the median. For testing statistical significance between distributions (including RNA expression and ChIP-
seq peak read counts), a two-tailed t test was used. For binned analyses, geneswere ranked by increasing expression, binned (number
of bins in each experiment detailed in figure and legend), andmeanwas plottedwith error bars representing the 95%confidence interval
of themeanasdeterminedbyempirical resamplingwith replacement (1000 iterations). Best fit line inbinnedanalyseswas added using a
locally weighted regression (loess). For bar charts of colony numbers, H3K27 acetylation, RNA expression by quantitative RT-PCR, and
ChIP-PCR, unless otherwise specified in figure or legend, bars represent themean of 3-4 replicates and error bars are standard error of
the mean. Statistical significance was compared by unpaired two-tailed t test, with P value < 0.05 considered significant. Gene set
enrichmentanalysis (GSEA)wasperformedusing1000permutationsbygeneset,maxsizeset 500,minsizeset15,weightedenrichment
statistic, genes ranked by Signal2Noise. The GSEA enrichment score reflects the degree to which a gene set is overrepresented at the
upper or lower endsof a ranked list of genes.A running-sumstatistic is generated from the ranked list of genes,with themagnitude of the
increment depending on the correlation of the genewith the phenotype. The enrichment score is themaximumdeviation from zero. The
false discovery rate (FDR) in GSEA is the estimated probability that a gene set with a given enrichment score represents a false positive,
and is calculated as a ratio of two distributions: (1) the actual enrichment score versus the enrichment score for all gene sets against all
permutations of the dataset, and (2) the actual enrichment score versus the enrichment score for all gene sets against the actual dataset.
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